GLY145ARG mutation emerging under HBIG treatment in patients with recurrent HBV after liver transplantation strongly reduces viral secretion.
Fischer
L
L
Department of Surgery, University Hospital Hamburg Eppendorf, Hamburg, Germany.
Kalinina
T
T
Rogiers
X
X
Will
H
H
Sterneck
M
M
D019943:Amino Acid Substitution; D001120:Arginine; D001426:Bacterial Proteins; D006528:Carcinoma, Hepatocellular; D004268:DNA-Binding Proteins / Q000032:analysis; D016679:Genome, Viral; D005998:Glycine; D006509:Hepatitis B / Q000235:genetics* / Q000601:surgery*; D006515:Hepatitis B virus / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000627:therapeutic use*; D008113:Liver Neoplasms; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010446:Peptide Fragments / Q000032:analysis; D012008:Recurrence; D012260:Ribonucleases / Q000032:analysis; D014162:Transfection; D014407:Tumor Cells, Cultured
D001426:Bacterial Proteins; D004268:DNA-Binding Proteins; D007136:Immunoglobulins; C116593:L-protein, Peptococcus magnus; D010446:Peptide Fragments; C023560:ribonuclease S-peptide; D001120:Arginine; D012260:Ribonucleases; D005998:Glycine; C045213:hepatitis B hyperimmune globulin